Matteo Lambertini, MD PhD· @matteolambe · X·· 22 hours agoScore70
Body
Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented by the great @antgiorda 🇮🇹 in patients with endocrine-resistant disease
@OncoAlert @myESMO @Annals_Oncology
228 views · 10 likes · 6 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgSource: Matteo Lambertini, MD PhD · x.com